Published in J Cachexia Sarcopenia Muscle on May 15, 2011
Efforts begin to sprout: publications in JCSM on cachexia, sarcopenia and muscle wasting receive attention. J Cachexia Sarcopenia Muscle (2014) 1.34
Understanding cachexia as a cancer metabolism syndrome. Oncogenesis (2016) 0.88
The role of triglyceride lipases in cancer associated cachexia. Trends Mol Med (2013) 0.88
Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. Arch Med Sci (2013) 0.85
A New Role for Browning as a Redox and Stress Adaptive Mechanism? Front Endocrinol (Lausanne) (2015) 0.79
Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget (2015) 0.79
Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia. Br J Cancer (2016) 0.78
Cancer Cachexia and MicroRNAs. Mediators Inflamm (2015) 0.78
Pitfalls in defining and quantifying cachexia. J Cachexia Sarcopenia Muscle (2011) 0.77
Cachexia Index in Advanced Non-Small-Cell Lung Cancer Patients. Clin Med Insights Oncol (2015) 0.76
The clinical picture of cachexia: a mosaic of different parameters (experience of 503 patients). BMC Cancer (2017) 0.75
Validation of the CAchexia SCOre (CASCO). Staging Cancer Patients: The Use of miniCASCO as a Simplified Tool. Front Physiol (2017) 0.75
Positive Prehabilitative Effect of Intense Treadmill Exercise for Ameliorating Cancer Cachexia Symptoms in a Mouse Model. J Cancer (2016) 0.75
Sarcopenia in gastric cancer: when the loss costs too much. Gastric Cancer (2017) 0.75
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 38.99
The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J (1985) 8.06
Cachexia: a new definition. Clin Nutr (2008) 5.49
Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr (2006) 2.67
Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle (2010) 2.49
Human body composition: in vivo methods. Physiol Rev (2000) 2.28
Therapy insight: Cancer anorexia-cachexia syndrome--when all you can eat is yourself. Nat Clin Pract Oncol (2005) 1.41
Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med (Berl) (2003) 1.38
The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin Pract (2006) 1.23
Handgrip dynamometry in healthy adults. Clin Nutr (2005) 1.22
Dual-energy X-ray absorptiometry and body composition. Curr Opin Clin Nutr Metab Care (2005) 1.21
Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg (1999) 1.16
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol (2008) 1.11
Evolving classification systems for cancer cachexia: ready for clinical practice? Support Care Cancer (2010) 1.10
Intravenous hyperalimentation. Effect on delayed cutaneous hypersensitivity in cancer patients. Ann Surg (1980) 1.10
The metabolic basis of cancer cachexia. Med Res Rev (1997) 1.10
Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Lett (2005) 1.09
The use of bioelectrical impedance analysis to predict total body water in patients with cancer cachexia. Am J Clin Nutr (1995) 1.07
Daily physical-rest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia. Clin Cancer Res (2007) 1.06
Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions. Crit Rev Clin Lab Sci (1993) 1.00
FORT and FORD: two simple and rapid assays in the evaluation of oxidative stress in patients with type 2 diabetes mellitus. Metabolism (2009) 0.97
Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clin Nutr (2007) 0.96
Physical activity level as an outcome measure for use in cancer cachexia trials: a feasibility study. Support Care Cancer (2009) 0.93
Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy. J Pain Symptom Manage (2007) 0.92
Bioelectric impedance spectroscopy underestimates fat-free mass compared to dual energy X-ray absorptiometry in incurable cancer patients. Eur J Clin Nutr (2008) 0.90
An interdisciplinary approach to manage cancer cachexia. Clin J Oncol Nurs (2010) 0.88
The need for a standardized definition for cachexia in chronic illness. Nat Clin Pract Endocrinol Metab (2006) 0.87
Impaired immune function: an early marker for cancer cachexia. Oncol Rep (2009) 0.86
Innate and acquired activation pathways in T cells. Nat Immunol (2001) 0.83
Nutritional markers and prognosis in cardiac cachexia. Int J Cardiol (2009) 0.81
Cancer-related cachexia and oxidative stress: beyond current therapeutic options. Expert Rev Anticancer Ther (2003) 0.77
Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha-lipoic acid and N-acetyl cysteine. Int J Cancer (2000) 0.76
Preoperative evaluation of lung cancer: predicting the impact of surgery on physiology and quality of life. Curr Opin Pulm Med (2008) 0.75
The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care (2009) 1.52
Training depletes muscle glutathione in patients with chronic obstructive pulmonary disease and low body mass index. Respiration (2006) 1.47
Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med (Berl) (2003) 1.38
Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care (2003) 1.20
Cancer cachexia: the molecular mechanisms. Int J Biochem Cell Biol (2003) 1.18
The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol (2005) 1.16
Overexpression of interleukin-15 induces skeletal muscle hypertrophy in vitro: implications for treatment of muscle wasting disorders. Exp Cell Res (2002) 1.16
Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Lett (2004) 1.16
Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition (2006) 1.16
Assessment of adiponectin and leptin as biomarkers of positive metabolic outcomes after lifestyle intervention in overweight and obese children. J Clin Endocrinol Metab (2008) 1.15
Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist (2007) 1.15
Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res (2004) 1.15
Muscle wasting in cancer: the role of mitochondria. Curr Opin Clin Nutr Metab Care (2015) 1.13
Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: evidence for a skeletal muscle-to-fat signaling pathway. Cell Biol Int (2005) 1.13
Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol (2004) 1.12
IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol (2006) 1.11
Cross-talk between skeletal muscle and adipose tissue: a link with obesity? Med Res Rev (2005) 1.10
Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle (2011) 1.09
Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Lett (2005) 1.09
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist (2010) 1.06
Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev (2004) 1.05
Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition (2005) 1.03
Redox balance and carbonylated proteins in limb and heart muscles of cachectic rats. Antioxid Redox Signal (2010) 1.02
Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. Biochim Biophys Acta (2002) 1.01
Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett (2006) 1.00
The role of uncoupling proteins in pathophysiological states. Biochem Biophys Res Commun (2002) 0.98
Are there any benefits of exercise training in cancer cachexia? J Cachexia Sarcopenia Muscle (2012) 0.98
Novel approaches to the treatment of cachexia. Drug Discov Today (2007) 0.98
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev (2006) 0.97
Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. J Cachexia Sarcopenia Muscle (2011) 0.97
Formoterol in the treatment of experimental cancer cachexia: effects on heart function. J Cachexia Sarcopenia Muscle (2014) 0.96
Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clin Nutr (2007) 0.96
Potassium channels are a new target field in anticancer drug design. Recent Pat Anticancer Drug Discov (2007) 0.96
Effects of interleukin-15 on lipid oxidation: disposal of an oral [(14)C]-triolein load. Biochim Biophys Acta (2006) 0.95
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters. J Exp Ther Oncol (2003) 0.95
Hemostasis alterations in metabolic syndrome (review). Int J Mol Med (2006) 0.95
Consensus on cachexia definitions. J Am Med Dir Assoc (2010) 0.95
Interleukin-15 increases glucose uptake in skeletal muscle. An antidiabetogenic effect of the cytokine. Biochim Biophys Acta (2006) 0.94
The AP-1/CJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia. FEBS Lett (2006) 0.94
Effects of IL-15 on rat brown adipose tissue: uncoupling proteins and PPARs. Obesity (Silver Spring) (2008) 0.94
Myostatin: more than just a regulator of muscle mass. Drug Discov Today (2012) 0.93
Cytokines as mediators and targets for cancer cachexia. Cancer Treat Res (2006) 0.93
Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol (2011) 0.93
Effects of eicosapentaenoic acid (EPA) treatment on insulin sensitivity in an animal model of diabetes: improvement of the inflammatory status. Obesity (Silver Spring) (2010) 0.93
Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med (Berl) (2009) 0.92
TNF-alpha modulates cytokine and cytokine receptors in C2C12 myotubes. Cancer Lett (2002) 0.92
Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency? Biochim Biophys Acta (2013) 0.91
Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. Int J Biochem Cell Biol (2008) 0.90
Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. Drug Discov Today (2008) 0.90
Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. Involvement of ROS in a model of mouse cancer cachexia. FEBS Lett (2005) 0.90
Production of inflammatory molecules in peripheral blood mononuclear cells from severely glucose-6-phosphate dehydrogenase-deficient subjects. J Vasc Res (2007) 0.89
Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration? J Cachexia Sarcopenia Muscle (2011) 0.89